Impact of cancer on cognitive trajectories in older adults

Active Project Grant Awarded Last action

Award ID
R01CA279316
Recipient
Awarding agency
Obligated
$2,798,050

Award facts

Assistance listing
93.393 Cancer Cause and Prevention Research
Completion date 51% complete
Place of performance
Boston, MA 02114, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Cancer-related cognitive impairment (crci) represents an important clinical issue affecting up to 75% of people before, during, and after diagnosis and treatment. Understanding cognitive trajectories associated with cancer and cancer treatment is particularly important among older adults (age ≥ 65) who may be more susceptible to crci. However, older adults have been underrepresented and previous studies have been limited by a predominance of short-term follow-up, focus on breast cancer, and a lack of mechanistic investigation. The overall objective of this application is to determine risk, susceptibility, and biological mechanisms linking cancer, cancer treatment and cognitive functioning. We will leverage data from aspree (aspirin in reducing events in the elderly) and its observational follow-up study (aspree-XT). Aspree was a trial of 19,114 individuals aged ≥70 years (≥ 65 for US minorities) enrolled in australia (n=16,703) or the united states (n=2,411) in which participants were randomly allocated to daily low-dose (100 MG) aspirin or placebo. At enrollment, participants had no history of diagnosed dementia, cardiovascular disease, significant physical disability, or major cognitive impairment. Repeated measures of multiple domains of cognitive function were performed, including memory, executive function, and psychomotor speed, assessed at baseline and every 2 years (2010-2017), and then annually during follow-up (2018-2024). We will use a prospective longitudinal study design to examine the following specific aims: aim 1. Determine the impact of cancer and cancer treatment on longitudinal trajectories of cognitive functioning. We will expand the cancer treatment data set to include treatment data for all cancer events through to 2024, and further investigate whether host factors such as age at diagnosis, assignment to aspirin or placebo, educational attainment, apoe risk genotype, dementia polygenic risk score, pre-diagnostic clonal hematopoiesis of indeterminant significance (chip), or biomarkers associated with alzheimer's disease and related dementias (adrd) neuropathology (AΒ, p-TAU, NFL, and gfap) impact risk. Aim 2. Determine the impact of cancer and cancer treatment on chip and adrd biomarkers (AΒ, p-TAU, NFL, and gfap) and investigate potential mediating effects with respect to cognitive functioning. This study is significant because IT addresses the high unmet need to elucidate the relationship between cancer and cancer treatment and cognitive functioning in older adults, to characterize pre-diagnostic factors that confer susceptibility, and identify mechanisms that underlie associations. In so doing, IT enables early detection of high-risk individuals. IT directly addresses the priorities outlined in not-CA-21-031. This study leverages a unique study population with longitudinal measures of cognitive function before and after cancer diagnosis, investigates cognitive trajectories, includes multiple cancer types, focuses on older adults, and advances mechanistic understanding of cancer- related cognitive impairment. The impact will be to help identify individuals at higher risk crci and the modifiable targets for intervention, ultimately improving quality of life and independent living.

Transactions

Action Obligated Date
Amendment $184,099
Amendment $310,323
Amendment $310,323
Amendment $170,829
Amendment -$121,388
Amendment $444,981
Amendment $444,981
Amendment $526,951
Original award $526,951

Subawards

Subrecipient Amount Awarded
Monash University In Australia, the Monash University ASPREE team, under the leadership of PI Dr Orchard, and in conjunction with PI Warner and with input from… $170,829
Monash University $195,284
Hennepin Healthcare Research Institute This site will be responsible for obtaining records and documentation necessary to determine cancer treatment received for all US cases diagnosed since the… $142,834

Quick answers

Who received award R01CA279316?

R01CA279316 was awarded to The General Hospital Corporation by National Cancer Institute (National Institutes of Health) on April 5, 2024.

How much is award R01CA279316 worth?

$2,798,050 has been obligated on R01CA279316.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login